

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/629,466
		Filing Date	07/29/2003
		First Named Inventor	A. Palani
		Art Unit	1625
		Examiner Name	Celia C. Chang
Sheet	1	of:	1
		Attorney Docket No.	IN01481KB

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	BILELLO et al., "Human Serum α_1 Acid Glycoprotein Reduces Uptake, Intracellular Concentration, and Antiviral Activity of A-80987, an Inhibitor of the Human Immunodeficiency Virus Type 1 Protease", Antimicrobial Agents and Chemotherapy, (June 1996), p. 1491-1497, Vol. 40, No. 6, American Society for Microbiology.	
	AB	BILELLO et al., "Reduction of the In Vitro Activity of A77003, an Inhibitor of Human Immunodeficiency Virus Protease, by Human Serum α_1 Acid Glycoprotein", The Journal of Infectious Diseases, (1995), p. 546-51, Vol. 171.	
	AC	BRYANT et al., "SC-52151, a Novel Inhibitor of the Human Immunodeficiency Virus Protease", Antimicrobial Agents and Chemotherapy, (October 1995), p. 2229-2234, Vol. 39, No. 10, American Society for Microbiology.	
	AD	FISCHL et al., "Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151", Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, (1997), p. 28-34, Vol. 15, No. 1, Lippincott-Raven Publishers, Philadelphia.	
	AE	GOLDBERG et al., "DuP 532, an angiotensin II receptor antagonist: First administration and Comparison with losartan", Clinical Pharmacology & Therapeutics, (January 1997), p. 59-69, Vol. 61, No. 1.	
	AF	MAILLARD et al., "Does protein binding modulate the effect of angiotensin II receptor antagonists?", Journal of the Renin-Angiotensin-Aldosterone System, (March 2001), p. S54-S58, Vol. 2, Supplement 1.	
	AG	TRAINOR, "The importance of plasma protein binding in drug discovery", Expert Opin. Drug Discov., (2007), p. 51-64, Vol. 2, No.1.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.